Gentuximab
- Generic Name
- Gentuximab
A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT05223595
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Phase 1
- Conditions
- Advanced Gastric or Gastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT04053205
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Fujian Tumor Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath